Decision model favors left atrial appendage occlusion over oral anticoagulants for stroke prevention in patients at highest risk for bleeding

A decision model found that the relative clinical benefit of left atrial appendage occlusion (LAAO) and oral anticoagulants (OAC) in patients with atrial fibrillation depends on the patients’ baseline risks for stroke and bleeding. LAAOs were found to be the preferred strategy in those with the highest bleeding risk. This benefit became less certain with increasing risk for ischemic stroke and decreasing bleeding risk. The findings are published in Annals of Internal Medicine.

Atrial fibrillation after non-cardiac surgery is common and not benign

A cohort study of persons with incident atrial fibrillation (AF) has found that AF after noncardiac surgery is common and comprises 13 percent of all new AF diagnoses. Postoperative AF is also associated with similar risk for stroke or transient ischemic attack (TIA) and death as AF unrelated to surgery. The findings are published in Annals of Internal Medicine.

Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement

Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial

Trial Finds High Doses of a Prescription Fish Oil Do Not Reduce Major Cardiac Events in High-Risk Patients

Cleveland: Findings from a new Cleveland Clinic study do not support the use of a high dose omega-3 fatty acid formulation to reduce major adverse cardiovascular events in patients with high cardiovascular risk.

Findings from the STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) In Patients With High Vascular Risk And Atherogenic Dyslipidemia were reported today during a Late Breaking Science session at the American Heart Association’s virtual Scientific Sessions 2020. The findings were also simultaneously published online in the Journal of the American Medical Association.